Funding for this research was provided by:
Japan Society for the Promotion of Science (JP17K10343)
Article History
Received: 1 August 2021
Accepted: 27 January 2022
First Online: 8 February 2022
Declarations
:
: The authors declare that they have no conflicts of interests associated with this manuscript. Akiyoshi Shimura has received fees from Dainihon Sumitomo Pharma, MSD, and Eisai outside of the submitted work. Takeshi Inoue has received personal compensation from GlaxoSmithKline, Mochida Pharmaceutical, Asahi Kasei Pharma, and Shionogi; grants from Astellas; and grants and personal compensation from Otsuka Pharmaceutical, Dainippon Sumitomo Pharma, Eli Lilly, Eisai, Mitsubishi Tanabe Pharma, Pfizer, AbbVie GK, MSD, Yoshitomiyakuhin, Takeda Pharmaceutical, and Meiji Seika Pharma; and is a member of the advisory boards of GlaxoSmithKline, Pfizer, Eli Lilly, Mochida Pharmaceutical, and Mitsubishi Tanabe Pharma outside of the submitted work.